Initial data from a phase I trial of Glaxosmithkline (GSK) plc's Ebola virus vaccine were published on Wednesday, showing the product is safe and immunogenic. The results were released as the first shipment of the vaccine reached one of the countries hit by the epidemic, with 300 vials arriving in Liberia, West Africa.